Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2024
0mins
Source: NASDAQ.COM
- Deciphera Pharmaceuticals Acquisition: ONO Pharmaceutical is acquiring Deciphera for $2.4 billion, offering a 74.7% premium per share.
- Qinlock Drug Portfolio: The acquisition includes Qinlock, a drug for gastrointestinal stromal tumors, with sales of $42.6 million in Q1 2024.
- Expansion Plans: Deciphera aims to expand Qinlock's label for second-line GIST treatment and has other drug candidates like vimseltinib and DCC-3116.
- Expected Benefits: ONO Pharmaceutical expects to strengthen its oncology market presence and accelerate business development in the US and EU through this acquisition.
- M&A Trends in Pharma Sector: The pharmaceutical sector sees aggressive M&A activities due to pipeline building needs, with a focus on oncology, rare diseases, and cell and gene therapy markets.
Analyst Views on ALXO
Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.470
Low
2.00
Averages
3.00
High
4.00
Current: 1.470
Low
2.00
Averages
3.00
High
4.00
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
